Telix Pharmaceuticals Limited (TLX,TLX.AX) on Tuesday reported a rise in revenue for the fourth quarter, helped by increased revenue from the Precision Medicine segment and RLS third-party.
For the three-month period to December 31, 2025, the company posted revenue of $208 million, higher than $142 million in the same period last year.
Revenue from the Precision Medicine segment moved up to $161 million from $139 million a year ago. RLS third-party revenue stood at $45 million, compared with $00.00 million last year.
TLX was down by 1.03% at $7.68 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.